Companies · Software / Tech
NATICK · Software / Tech · refined from filed group “Other Health Care”
Diligence memoA one-page analyst read on Allurion Technologies, Inc. — recommendation, valuation, rhythm, risks.→Allurion Technologies, Inc. looks under-valued against its niche peers and is active on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the technology sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Allurion Technologies, Inc. is one of 3920 Software / Tech companies tracked from NATICK. By capital raised it ranks in the upper tier (ahead of 88% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.
Round size and date are reported; the stage label is inferred from round size (latest is Series B — a $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the technology sector profile. Directional, not a quoted figure.
Benchmarked against 3920 companies in Software / Tech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 88% of sector peers (real $). Modeled value above 42% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #83 of 95.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Machina Labs, Inc. | Series B | $70.2M | $205.6M | 2.07× |
| Metaview Technologies Inc. | Series B | $51.7M | $198.0M | 2.00× |
| Felix Technologies Inc. | Series B | $61.1M | $194.6M | 1.96× |
| Foxglove Technologies Inc. | Series B | $58.0M | $190.8M | 1.92× |
| NetBox Labs, Inc. | Series B | $53.3M | $184.8M | 1.86× |
| Omni Design Technologies, Inc. | Series B | $34.3M | $182.7M | 1.84× |
| Alaffia Technology Solutions, Inc. | Series B | $57.3M | $182.6M | 1.84× |
| Rivington Labs Inc. | Series B | $59.6M | $176.4M | 1.78× |
| Labs Companies, Inc. | Series B | $57.5M | $175.4M | 1.77× |
| Reveal Technology, Inc. | Series B | $28.5M | $159.7M | 1.61× |
| Architect Financial Technologies Inc. | Series B | $52.5M | $158.8M | 1.60× |
| Pylon Labs, Inc. | Series B | $49.7M | $156.3M | 1.58× |
| Allurion Technologies, Inc. this company | Series B | $36.1M | $23.1M | 0.23× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Seed | $1.7M | 2012-07-12 | $8.3M | $56.5M | 85% |
| Seed | $1.3M | 2013-04-05 | $6.3M | $42.6M | 85% |
| Seed | $1.6M | 2014-07-15 | $8.1M | $55.2M | 85% |
| Series B | $19.0M | 2017-01-17 | $105.7M | $579.3M | 90% |
| Series B | $123K | 2023-12-18 | $681K | $1.1M | 90% |
| Series B | $7.4M | 2025-01-27 | $41.3M | $45.4M | 90% |
| Series B | $5.0M | 2025-11-14 | $27.8M | $23.1M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Krishna Gupta | — | 8 other | 2025-01 |
| Larson Douglas Hudson | — | 2 other | 2025-01 |
| Michael Davin | — | 1 other | 2025-01 |
| Omar Ishrak | — | 1 other | 2025-01 |
| Benoit Jacques Claude Chardon | — | — | 2023-12 |
| Brendan Gibbons | — | — | 2025-01 |
| Chris Geberth | — | — | 2023-12 |
| Douglas Hudson Larson | — | — | 2023-12 |
| Jonathan D Wecker | — | — | 2012-07 |
| Keith Douglas Johns | — | — | 2025-01 |
| Krishna D Gupta | — | — | 2017-01 |
| Krishna Jacques Claude Gupta | — | — | 2023-12 |
| Michael Jacques Claude Davin | — | — | 2023-12 |
| Milena Douglas Alberti-Perez | — | — | 2025-01 |
| Neil D Chheda | — | — | 2017-01 |
| Nicholas Douglas Lewin | — | — | 2025-01 |
| Nicholas Hudson Lewin | — | — | 2023-12 |
| Ojas Buch | — | — | 2025-01 |
| Omar Jacques Claude Ishrak | — | — | 2023-12 |
| Ram Chuttani | — | — | 2012-07 |
| R. Jason Douglas Richey | — | — | 2025-01 |
| Samuel G Levy | — | — | 2012-07 |
| Shantanu Gaur | — | — | 2023-12 |
| Shantanu K Gaur | — | — | 2012-07 |
Allurion Technologies, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| CMS Technology, Inc. | Software / Tech | Series B | $35.9M | $28.9M | same sector · same stage |
| Upshot Technologies, Inc. | Software / Tech | Series B | $34.8M | $22.8M | same sector · same stage |
| Redica Systems, Inc. | Software / Tech | Series B | $39.5M | $27.9M | same sector · same stage |
| Prismatic Software Inc. | Software / Tech | Series B | $30.7M | $22.1M | same sector · same stage |
| LIS Technologies Inc | Software / Tech | Series B | $64.5M | $28.7M | same sector · same stage |
| Presto Phoenix, Inc. | Other Technology | Series B | $28.0M | $44.4M | network1 shared operator · same stage |
| Matrix Analytics, Inc. | Software / Tech | Series B | $19.7M | $26.4M | same sector · same stage |
| NoHo Wellness, Inc. | Healthtech | Series B | $27.2M | $474.3M | network1 shared operator · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Jaxon Technologies, LLC | Software / Tech | Series A | $144.2M | 84% |
| Allora Health Inc. | Healthtech | Series A | $38.5M | 83% |
| Revon Systems, Inc. | Software / Tech | Seed | $15.5M | 82% |
| samark technology Corp | Software / Tech | Pre-Seed | $4.2M | 82% |
| SomnoMed Technologies Inc. | Software / Tech | Pre-Seed | $3.7M | 82% |
| Limerick Technologies, Inc. | Software / Tech | Pre-Seed | $2.3M | 82% |
| InterShunt Technologies, Inc. | Software / Tech | Series B | $168.5M | 82% |
| NeuX Technologies, Inc. | Software / Tech | Seed | $51.1M | 82% |
See where Allurion Technologies, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Allurion Technologies, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.